UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $170.41 Million Stock Holdings in The Clorox Company $CLX

Key Points

• UBS AM increased its holdings in The Clorox Company by 3.7% during the 1st quarter, owning approximately 1.16 million shares worth $170.41 million.
• Clorox reported earnings of $2.87 per share, surpassing expectations, with a 4.5% increase in quarterly revenue year-over-year.
• The company recently raised its quarterly dividend to $1.24, reflecting an annualized yield of 4.0% and a payout ratio of 76.07%.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 3.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,157,257 shares of the company's stock after buying an additional 41,485 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.94% of Clorox worth $170,406,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. lifted its holdings in Clorox by 15.6% during the 1st quarter. Raymond James Financial Inc. now owns 269,926 shares of the company's stock worth $39,747,000 after buying an additional 36,352 shares in the last quarter. OneDigital Investment Advisors LLC acquired a new position in shares of Clorox in the 1st quarter valued at $247,000. Brown Miller Wealth Management LLC acquired a new position in shares of Clorox in the 1st quarter valued at $399,000. Roman Butler Fullerton & Co. acquired a new position in shares of Clorox in the 1st quarter valued at $400,000. Finally, Wedge Capital Management L L P NC lifted its stake in shares of Clorox by 33.5% in the 1st quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company's stock valued at $4,198,000 after purchasing an additional 7,159 shares during the period. Institutional investors and hedge funds own 78.53% of the company's stock.

Clorox Price Performance

NYSE:CLX opened at $124.44 on Friday. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The stock's 50-day simple moving average is $124.30 and its 200 day simple moving average is $132.67. The company has a market cap of $15.22 billion, a P/E ratio of 19.09, a P/E/G ratio of 0.99 and a beta of 0.52. The Clorox Company has a 52-week low of $116.53 and a 52-week high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. The business had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.Clorox's quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, sell-side analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Wednesday, August 13th were given a $1.24 dividend. This is an increase from Clorox's previous quarterly dividend of $1.22. This represents a $4.96 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Wednesday, August 13th. Clorox's dividend payout ratio (DPR) is presently 76.07%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CLX. UBS Group cut their price target on Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Barclays cut their price target on Clorox from $129.00 to $119.00 and set an "underweight" rating on the stock in a research note on Tuesday, July 15th. Wells Fargo & Company cut their price target on Clorox from $138.00 to $130.00 and set an "equal weight" rating on the stock in a research note on Friday, September 5th. Morgan Stanley lowered their price objective on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Finally, Jefferies Financial Group lowered their price objective on shares of Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Reduce" and a consensus price target of $142.18.

Insider Activity

In related news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.57% of the company's stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.